Monopar Therapeutics Q2 2026 net loss widens to $5.3 million, or $0.62 per share
Monopar Therapeutics reported second quarter 2026 results with a net loss of $5.3 million, or $0.62 per share, up from $2.5 million, or $0.35 per share, a year earlier. The company said R&D spending rose as it prepares a potential ALXN1840 launch, and it reported $134.3 million in cash as of June 30, 2026.
Key points
- Net loss was $5.3 million, or $0.62 per share, versus $2.5 million, or $0.35 per share, in Q2 2025.
- R&D expenses were $4,766,832, up from $1,730,000, mainly due to a $2,026,851 increase in contractor and consulting costs.
- Cash, cash equivalents and investments were $134.3 million at June 30, 2026, which the company says will support operations through at least December 31, 2027.
- The company began a rolling NDA submission for ALXN1840 for Wilson disease on July 22, 2026, and expects to complete it within the next few months.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.